Intraindividual comparison of gadoxetate disodium - Enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis

Radiology

Volumn 256, Issue 3, 2010, Pages 806-816

  Di Martino, Michele ^a   Marin, Daniele ^a,b   Guerrisi, Antonino ^a   Baski, Mahbubeh ^a   Galati, Francesca ^a   Rossi, Massimo ^a   Brozzetti, Stefania ^a   Masciangelo, Raffaele ^a   Passariello, Roberto ^a   Catalano, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOXETIC ACID; IOMEPROL;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL EXAMINATION; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVER VARIATION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SENSITIVITY ANALYSIS; STANDARD; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77956125803     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091334     Document Type: Article

References (41)

1. Peterson MS, Baron RL, Marsh JW Jr, Oliver JH 3rd, Confer SR, Hunt LE. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000;217(3):743-749.
2. Lim JH, Kim CK, Lee WJ, et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000;175(3):693-698.
3. Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219(2):445-454.
4. Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002;8(12):1156-1164.
5. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001;218(1):27-38.
6. Gadoxetate disodium: label and approval history. U.S. Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction= Search.Label-ApprovalHistory#apphist. Updated September 6, 2010. Accessed September 6, 2010.
7. Yamashita Y, Mitsuzaki K, Yi T, et al. Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 1996;200(1):79-84. (Pubitemid 26197342)
8. Oi H, Murakami T, Kim T, Matsushita M, Kishimoto H, Nakamura H. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR Am J Roentgenol 1996;166(2):369-374.
9. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200(1):59-67.
10. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist) enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18(3):457-467.
11. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005;237(1):89-98.
12. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intra-operative findings. Radiology 2004;230(1):266-275.
13. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006;30(3):345-354.
14. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid- enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192(6):1675-1681.
15. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology 2003;226(1):24-28. (Pubitemid 36163903)
16. Heiken JP, Brink JA, McClennan BL, Sagel SS, Crowe TM, Gaines MV. Dynamic incremental CT: effect of volume and concentration of contrast material and patient weight on hepatic enhancement. Radiology 1995; 195(2):353-357.
17. Huda W, Ogden KM, Khorasani MR. Converting dose-length product to effective dose at CT. Radiology 2008;248(3):995-1003.
18. Kanematsu M, Semelka RC, Matsuo M, et al. Gadolinium-enhanced MR imaging of the liver: optimizing imaging delay for hepatic arterial and portal venous phases - a prospective randomized study in patients with chronic liver damage. Radiology 2002; 225(2):407-415.
19. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5): 1208-1236.
20. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47(1):97-104.
21. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42(1):27-34. (Pubitemid 40911308)
22. Yu JS, Chung JJ, Kim JH, Kim KW. Large (>or=2 cm) non-hypervascular nodules depicted on MRI in the cirrhotic liver: fate and implications. Clin Radiol 2008;63(10):1121-1130.
23. Chung JJ, Yu JS, Kim JH, Kim MJ, Kim KW. Nonhypervascular hypoattenuating nodules depicted on either portal or equilibrium phase multiphasic CT images in the cirrhotic liver. AJR Am J Roentgenol 2008;191(1): 207-214.
24. Grazioli L, Olivetti L, Fugazzola C, et al. The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol 1999;9(1): 62-67.
25. Martín J, Sentís M, Zidan A, et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995;195(1):125-130.
26. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005;234(2):468-478.
27. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009;193(4):1053-1060.
28. Elsayes KM, Narra VR, Yin Y, Mukundan G, Lammle M, Brown JJ. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradientecho MR imaging. RadioGraphics 2005; 25(5):1299-1320.
29. Couinaud C. Le foie: études anatomiques et chirurgicales. Paris, France : Masson, 1957; 9-12.
30. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982; 6(1):3-9. (Pubitemid 12066476)
31. Terminology of nodular hepatocellular lesions. International Working Party . Hepatology 1995;22(3):983-993.
32. Schwenke C, Busse R. Analysis of differences in proportions from clustered data with multiple measurements in diagnostic studies. Methods Inf Med 2007;46(5): 548-552.
33. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
34. Bigourdan JM, Jaeck D, Meyer N, et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 2003;9(5):513-520.
35. Figueras J, Jaurrieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000;190(5):580-587.
36. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47(1):82-89.
37. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 2003; 180(4):1007-1014. (Pubitemid 36363042)
38. Mettler FA Jr, Thomadsen BR, Bhargavan M, et al. Medical radiation exposure in the U.S. in 2006: preliminary results. Health Phys 2008;95(5):502-507.
39. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med 2007;357(22):2277-2284.
40. Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248(1):254-263.
41. Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. RadioGraphics 2008; 28(7):1983-1998.